| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | David H. Miller | Q104696550 |
| Laura J. Balcer | Q66764405 | ||
| P2093 | author name string | Stephen C Reingold | |
| Jeffrey A Cohen | |||
| P2860 | cites work | Validation and test characteristics of a 10-item neuro-ophthalmic supplement to the NEI-VFQ-25 | Q79259326 |
| Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite | Q79324031 | ||
| Pars planitis: a 20-year study of incidence, clinical features, and outcomes | Q79956707 | ||
| Correlation between full-field and multifocal VEPs in optic neuritis | Q80751883 | ||
| Relation of vision to global and regional brain MRI in multiple sclerosis | Q81325284 | ||
| Evaluation of minimum clinically meaningful changes in scores on the National Eye Institute Visual Function Questionnaire (NEI-VFQ) SST Report Number 19 | Q81354065 | ||
| Memantine for axonal loss of optic neuritis | Q82980533 | ||
| Early factors associated with axonal loss after optic neuritis | Q83099852 | ||
| Transsynaptic retinal degeneration in optic neuropathies: optical coherence tomography study | Q83185348 | ||
| Sustained motion perception deficit following optic neuritis: Behavioral and cortical evidence | Q84353395 | ||
| Reduced retinal nerve fiber layer thickness and macular volume in pediatric multiple sclerosis | Q84509765 | ||
| Persistent ocular motor manifestations and related visual consequences in multiple sclerosis | Q84996231 | ||
| Optic neuritis | Q86940073 | ||
| The clinical spectrum of microcystic macular edema | Q87048184 | ||
| Stratus OCT Quality Control in Two Multi-Centre Multiple Sclerosis Clinical Trials | Q91168115 | ||
| Association of retinal and macular damage with brain atrophy in multiple sclerosis | Q21135504 | ||
| Defining the clinical course of multiple sclerosis: the 2013 revisions | Q22241654 | ||
| Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up | Q24650224 | ||
| Optical coherence tomography: a window into the mechanisms of multiple sclerosis | Q24655514 | ||
| Mesenchymal stem cell transplantation in multiple sclerosis | Q26999783 | ||
| A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis | Q28270998 | ||
| Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis | Q28271008 | ||
| Optic nerve magnetisation transfer ratio after acute optic neuritis predicts axonal and visual outcomes. | Q30583486 | ||
| Subretinal abscess causing restricted diffusion on magnetic resonance imaging | Q30650375 | ||
| Self-reported visual dysfunction in multiple sclerosis: new data from the VFQ-25 and development of an MS-specific vision questionnaire | Q30691130 | ||
| Multifocal VEP and OCT in optic neuritis: a topographical study of the structure-function relationship | Q30847634 | ||
| Macular segmentation with optical coherence tomography | Q33215776 | ||
| Mapping of macular substructures with optical coherence tomography for glaucoma diagnosis | Q33304934 | ||
| Retinal imaging by laser polarimetry and optical coherence tomography evidence of axonal degeneration in multiple sclerosis | Q33351599 | ||
| Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis | Q33611158 | ||
| What is low vision? A re-evaluation of definitions | Q33638327 | ||
| Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis | Q33648360 | ||
| Recent developments in the assessment of quality of life in multiple sclerosis (MS). | Q33722681 | ||
| Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration | Q33882723 | ||
| Radial diffusivity in remote optic neuritis discriminates visual outcomes. | Q33899862 | ||
| Retinal architecture and mfERG: Optic nerve head component response characteristics in MS | Q33927190 | ||
| Visual field profile of optic neuritis: a final follow-up report from the optic neuritis treatment trial from baseline through 15 years | Q33938131 | ||
| Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis | Q33983613 | ||
| Vision in multiple sclerosis: the story, structure-function correlations, and models for neuroprotection | Q34076168 | ||
| Pediatric optic neuritis and risk of multiple sclerosis: meta-analysis of observational studies | Q34080426 | ||
| Development of the 25-item National Eye Institute Visual Function Questionnaire | Q34083677 | ||
| Color vision is strongly associated with retinal thinning in multiple sclerosis. | Q34145469 | ||
| Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis | Q46889760 | ||
| Visual acuity as an outcome measure in clinical trials of retinal diseases | Q46972408 | ||
| How sensitive to clinical change are ETDRS logMAR visual acuity measurements? | Q47734224 | ||
| Serial magnetization transfer imaging in acute optic neuritis | Q48088940 | ||
| Recovery from optic neuritis: an ROI-based analysis of LGN and visual cortical areas | Q48181935 | ||
| Persistent visual impairment in multiple sclerosis: prevalence, mechanisms and resulting disability | Q48285855 | ||
| Neuroplasticity predicts outcome of optic neuritis independent of tissue damage. | Q48291974 | ||
| Thalamic neurodegeneration in multiple sclerosis. | Q48459257 | ||
| The clinical features, MRI findings, and outcome of optic neuritis in children. | Q48463712 | ||
| Dissecting structure-function interactions in acute optic neuritis to investigate neuroplasticity. | Q48491625 | ||
| Pediatric optic neuritis: brain MRI abnormalities and risk of multiple sclerosis. | Q48710893 | ||
| Simvastatin improves final visual outcome in acute optic neuritis: a randomized study. | Q48896378 | ||
| A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. | Q50916632 | ||
| Treatment of steroid-unresponsive optic neuritis with plasma exchange. | Q50996129 | ||
| Dynamics of saccade parameters in multiple sclerosis patients with fatigue. | Q51331068 | ||
| Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity. | Q51842672 | ||
| Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. | Q52607108 | ||
| Impairment of contrast visual acuity as a functional correlate of retinal nerve fibre layer thinning and total macular volume reduction in multiple sclerosis. | Q52897530 | ||
| Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. | Q53171007 | ||
| Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. | Q53360219 | ||
| Quantifying axonal loss after optic neuritis with optical coherence tomography. | Q53621556 | ||
| Hidden visual loss in optic neuropathy is revealed using Gabor patch contrast perimetry. | Q53976181 | ||
| Dynamic formation of macular microcysts independent of vitreous traction changes | Q56957466 | ||
| Electropysiologic Evaluation of the Visual Pathway in Patients With Multiple Sclerosis | Q59697327 | ||
| Gray matter atrophy is related to long-term disability in multiple sclerosis | Q61861932 | ||
| Visual function in multiple sclerosis | Q69470750 | ||
| Correlation between morphological and functional retinal impairment in multiple sclerosis patients | Q73049039 | ||
| The National Eye Institute Visual Function Questionnaire: experience of the ONTT. Optic Neuritis Treatment Trial | Q73640346 | ||
| A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis | Q74009730 | ||
| Multiple sclerosis associated with uveitis in two large clinic-based series | Q77916396 | ||
| Decreased amplitudes in multiple sclerosis patients with normal visual acuity: a VEP study | Q78608101 | ||
| Scanning laser polarimetry reveals status of RNFL integrity in eyes with optic nerve head swelling by OCT | Q34192118 | ||
| Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. | Q34376913 | ||
| Eye disorders in patients with multiple sclerosis: natural history and management | Q34399820 | ||
| Low contrast visual acuity testing is associated with cognitive performance in multiple sclerosis: a cross-sectional pilot study | Q34481282 | ||
| Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis | Q34583794 | ||
| Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial | Q34611762 | ||
| Natalizumab reduces visual loss in patients with relapsing multiple sclerosis | Q34619715 | ||
| Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS. | Q34624396 | ||
| Gray matter atrophy in multiple sclerosis: a longitudinal study | Q34801849 | ||
| Optic neuritis is associated with inner nuclear layer thickening and microcystic macular edema independently of multiple sclerosis | Q34936918 | ||
| Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing-remitting multiple sclerosis | Q34992546 | ||
| Diffusion tensor imaging of the optic nerve in multiple sclerosis: association with retinal damage and visual disability | Q35300746 | ||
| Recovery from optic neuritis is associated with a change in the distribution of cerebral response to visual stimulation: a functional magnetic resonance imaging study | Q35456378 | ||
| Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study | Q35757641 | ||
| Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis | Q35762462 | ||
| Plasma exchange for severe optic neuritis: treatment of 10 patients | Q35903461 | ||
| Electrophysiological assessment of optic nerve disease | Q35944042 | ||
| Microcystic macular oedema in multiple sclerosis is associated with disease severity | Q35986688 | ||
| Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss | Q36129196 | ||
| Retinal ganglion cell layer volumetric assessment by spectral-domain optical coherence tomography in multiple sclerosis: application of a high-precision manual estimation technique | Q36143046 | ||
| Ocular manifestations of multiple sclerosis | Q36262880 | ||
| Diffusion tensor imaging in acute optic neuropathies: predictor of clinical outcomes | Q36371516 | ||
| Sex-specific differences in retinal nerve fiber layer thinning after acute optic neuritis | Q36475281 | ||
| Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study | Q36496806 | ||
| The diagnostic and prognostic value of neurofilament heavy chain levels in immune-mediated optic neuropathies. | Q36500261 | ||
| Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning | Q36659432 | ||
| Ganglion cell loss in relation to visual disability in multiple sclerosis | Q36781704 | ||
| One eye or two: a comparison of binocular and monocular low-contrast acuity testing in multiple sclerosis | Q36799833 | ||
| Modeling axonal degeneration within the anterior visual system: implications for demonstrating neuroprotection in multiple sclerosis | Q37057010 | ||
| Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis | Q37253834 | ||
| Development of a high-resolution fat and CSF-suppressed optic nerve DTI protocol at 3T: application in multiple sclerosis. | Q37267155 | ||
| The afferent visual pathway: designing a structural-functional paradigm of multiple sclerosis | Q37316388 | ||
| Retinal periphlebitis is associated with multiple sclerosis severity | Q37451100 | ||
| Detection of macular ganglion cell loss in glaucoma by Fourier-domain optical coherence tomography | Q37456437 | ||
| Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy. | Q37536318 | ||
| Monocular and binocular low-contrast visual acuity and optical coherence tomography in pediatric multiple sclerosis | Q37661189 | ||
| Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. | Q37781166 | ||
| The King-Devick (K-D) test of rapid eye movements: a bedside correlate of disability and quality of life in MS. | Q39171921 | ||
| Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria | Q39172867 | ||
| Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS. | Q39626623 | ||
| The time course and phenotype of Uhthoff phenomenon following optic neuritis. | Q39678531 | ||
| Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain | Q39693808 | ||
| Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity | Q39876379 | ||
| Adaptive cortical plasticity in higher visual areas after acute optic neuritis | Q40428057 | ||
| New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis | Q40759466 | ||
| Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force | Q40881098 | ||
| Clinical outcomes assessment in multiple sclerosis | Q41105997 | ||
| Improvement of internuclear ophthalmoparesis in multiple sclerosis with dalfampridine | Q41818641 | ||
| Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin | Q42595540 | ||
| A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials | Q43010508 | ||
| Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis | Q43245388 | ||
| Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis | Q43438570 | ||
| Neuro-ophthalmologic evaluation, quality of life, and functional disability in patients with MS. | Q43755865 | ||
| A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group | Q43800957 | ||
| Temporal reorganization to overcome monocular demyelination | Q44122359 | ||
| Evaluation of the effect of aging on retinal nerve fiber layer thickness measured by optical coherence tomography | Q44469071 | ||
| Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome | Q45788375 | ||
| Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain), 2008-2012. | Q45970017 | ||
| Retinal nerve fiber thickness in inflammatory demyelinating diseases of childhood onset. | Q45998742 | ||
| Visual field profile of optic neuritis. One-year follow-up in the Optic Neuritis Treatment Trial | Q46149388 | ||
| Optical coherence tomography in multiple sclerosis: thickness of the retinal nerve fiber layer as a potential measure of axonal loss and brain atrophy | Q46339932 | ||
| Treatment of acute optic neuritis: a summary of findings from the optic neuritis treatment trial | Q46484740 | ||
| Tracking retinal nerve fiber layer loss after optic neuritis: a prospective study using optical coherence tomography | Q46523193 | ||
| Age-related losses of retinal ganglion cells and axons | Q46551164 | ||
| Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis | Q46630997 | ||
| "Seeing" in NARCOMS: a look at vision-related quality of life in the NARCOMS registry | Q46755025 | ||
| An investigation of the retinal nerve fibre layer in progressive multiple sclerosis using optical coherence tomography | Q46868407 | ||
| Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis | Q46869606 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P433 | issue | Pt 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | eye disease | Q3041498 |
| multiple sclerosis | Q8277 | ||
| ocular vision | Q69942028 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 11-27 | |
| P577 | publication date | 2014-11-28 | |
| 2015-01-01 | |||
| P1433 | published in | Brain | Q897386 |
| P1476 | title | Vision and vision-related outcome measures in multiple sclerosis | |
| P478 | volume | 138 |
| Q90136377 | 14th EUNOS Congress: PORTO, PORTUGAL, 16-19 JUNE 2019 |
| Q33727044 | A conceptual model for vision rehabilitation |
| Q38709464 | A window to beyond the orbit: the value of optical coherence tomography in non-ocular disease |
| Q43154346 | Acute optic neuritis: a clinical paradigm for evaluation of neuroprotective and restorative strategies? |
| Q47216283 | Anatomical Wiring and Functional Networking Changes in the Visual System Following Optic Neuritis |
| Q91864455 | Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential |
| Q33692583 | Blocking LINGO-1 in vivo reduces degeneration and enhances regeneration of the optic nerve |
| Q50066134 | Clemastine fumarate for promotion of optic nerve remyelination. |
| Q55426467 | Comparison of probabilistic tractography and tract-based spatial statistics for assessing optic radiation damage in patients with autoimmune inflammatory disorders of the central nervous system. |
| Q35883802 | Delayed P100-Like Latencies in Multiple Sclerosis: A Preliminary Investigation Using Visual Evoked Spread Spectrum Analysis |
| Q39006910 | Diagnosis and clinical features of common optic neuropathies |
| Q47220919 | Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria |
| Q37741163 | Diffusion MRI quantifies early axonal loss in the presence of nerve swelling |
| Q42361527 | Diffusion tensor imaging for multilevel assessment of the visual pathway: possibilities for personalized outcome prediction in autoimmune disorders of the central nervous system. |
| Q92244011 | Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? |
| Q45151446 | Early retinal atrophy predicts long-term visual impairment after acute optic neuritis. |
| Q36511714 | Elevation of AQP4 and selective cytokines in experimental autoimmune encephalitis mice provides some potential biomarkers in optic neuritis and demyelinating diseases |
| Q38684135 | Functional connectivity alterations in a murine model of optic neuritis |
| Q33827241 | Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in bona fide multiple sclerosis |
| Q37615358 | Intranasal Delivery of A Novel Amnion Cell Secretome Prevents Neuronal Damage and Preserves Function In A Mouse Multiple Sclerosis Model |
| Q33692563 | Introducing a new method to assess vision: Computer-adaptive contrast-sensitivity testing predicts visual functioning better than charts in multiple sclerosis patients |
| Q35855972 | Investigating Tissue Optical Properties and Texture Descriptors of the Retina in Patients with Multiple Sclerosis |
| Q38797002 | Justification for conducting neurological clinical trials as part of patient care within private practice |
| Q38979382 | Length of optic nerve double inversion recovery hypersignal is associated with retinal axonal loss. |
| Q41484449 | Long-term structural retinal changes in patients with optic neuritis related to multiple sclerosis |
| Q64075118 | Macular ganglion cell complex parameters by optical coherence tomography in cases of multiple sclerosis without optic neuritis compared to healthy eyes |
| Q50331925 | Mechanism of delayed conduction of fellow eyes in patients with optic neuritis. |
| Q37275299 | Modeling the Chronic Loss of Optic Nerve Axons and the Effects on the Retinal Nerve Fiber Layer Structure in Primary Disorder of Myelin. |
| Q58586681 | Multiple sclerosis |
| Q51327401 | Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. |
| Q38952007 | Neuroprotection by central nervous system remyelination: Molecular, cellular, and functional considerations |
| Q41335521 | Neuroprotection by eIF2α-CHOP inhibition and XBP-1 activation in EAE/optic neuritiss. |
| Q28076588 | Optical Coherence Tomography and Magnetic Resonance Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder |
| Q52542431 | Optical coherence tomography angiography enhances the detection of optic nerve damage in multiple sclerosis. |
| Q31160866 | Outcome Measures in Clinical Trials for Multiple Sclerosis. |
| Q52845476 | Patients with multiple sclerosis demonstrate reduced subbasal corneal nerve fibre density. |
| Q37653515 | Pattern of gray matter volumes related to retinal thickness and its association with cognitive function in relapsing-remitting MS |
| Q47567504 | Perceptions on the value of bodily functions in multiple sclerosis |
| Q89397480 | Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview |
| Q88035379 | Phenytoin for neuroprotection - Authors' reply |
| Q39377591 | Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. |
| Q48193596 | Phenytoin: its potential as neuroprotective and retinoprotective drug |
| Q55010300 | Predictors of vision impairment in Multiple Sclerosis. |
| Q36058632 | Quantifying visual pathway axonal and myelin loss in multiple sclerosis and neuromyelitis optica |
| Q43121362 | Quantitative visual tests after poorly recovered optic neuritis due to multiple sclerosis |
| Q54967864 | Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis. |
| Q46227382 | Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis |
| Q55402326 | Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers. |
| Q64280813 | Silicone oil-induced ocular hypertension and glaucomatous neurodegeneration in mouse |
| Q26779897 | Symptomatic management in multiple sclerosis |
| Q90280173 | Targeted Krüppel-Like Factor 4 Gene Knock-Out in Retinal Ganglion Cells Improves Visual Function in Multiple Sclerosis Mouse Model |
| Q47097507 | The Contribution of Optical Coherence Tomography in Neuromyelitis Optica Spectrum Disorders. |
| Q47426363 | The Effect of In-School Saccadic Training on Reading Fluency and Comprehension in First and Second Grade Students |
| Q47975873 | The loss of macular ganglion cells begins from the early stages of disease and correlates with brain atrophy in multiple sclerosis patients |
| Q31162456 | Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis |
| Q54581509 | Vision Loss in a Teenage Girl With Postconcussion Syndrome. |
| Q64068110 | Vision and Vision-Related Measures in Progressive Multiple Sclerosis |
| Q47860010 | White matter tract-specific quantitative analysis in multiple sclerosis: Comparison of optic radiation reconstruction techniques. |
| Q50100449 | [New aspects of symptomatic MS treatment: Part 4-sexual dysfunction and eye movement disorders]. |
Search more.